Exagen reports record FY 2025 revenue of $66.6M, up 20% YoY; guides FY 2026 revenue $70-73M

EXAGEN INC.

Full-year 2025 revenue $66.6M (+20% YoY); Q4 2025 revenue $16.6M.
Full-year net loss $19.95M; adjusted EBITDA loss $9.79M; gross margin 58.3%.
AVISE CTD test volume grew >11% YoY; trailing 12-month ASP rose to $441 (+7%).
FY 2026 revenue guidance of $70M to $73M; path to cash flow positivity.
Year-end cash $32.4M; strengthened by $20M equity offering and $25M credit facility.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EXAGEN INC. reported the fourth quarter and full year ended December 31, 2025 results: revenue $16,631, net income $(4,673). Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $16,631
Net income: $(4,673)
Guidance: initiated
Result: reported results

Exact text from the filing

and full year ended December 31, 2025, and recent business highlights. Three Months Ended December 31, Year Ended December 31, 2025 2025 (in thousands, except ASP data) Revenue $ 16,631 $ 66,575 Gross margin 55.4 % 58.3 % Operating expenses $ 14,181 $ 52,869 Loss from operations $ (4,975) $ (14,070) Net loss $ (4,673) $ (19,951) Adjusted EBITDA $ (3,670) $

View on SEC.gov

Browse all earnings releases →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.